Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 7/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12224896 | 0.86 | HRH4 (0.66) | HRH4HRH3TRPV4NSD2PKM | |
| SCHEMBL12224793 | 0.86 | HRH4 (0.38) | HRH4HRH3HTTCCNCCDK8 | |
| SCHEMBL12224922 | 0.84 | HRH4 (0.52) | HRH4HRH3HTTTRPV4NSD2 | |
| SCHEMBL406905 | 0.82 | HRH4 (0.52) | HRH4HRH3HTTTRPV4CCNC | |
| SCHEMBL2464217 | 0.80 | HRH4 (0.53) | HRH4HRH3HTTTRPV4NSD2 | |
| SCHEMBL12224899 | 0.80 | HRH4 (0.53) | HRH4HRH3HTTTRPV4NSD2 | |
| SCHEMBL12224893 | 0.80 | HRH4 (0.55) | HRH4HRH3HTTNSD2PKM | |
| SCHEMBL2469152 | 0.79 | HRH4 (0.57) | HRH4HRH3TRPV4NSD2PKM | |
| SCHEMBL12224926 | 0.78 | HRH4 (0.44) | HRH4HRH3HTTNSD2PKM | |
| SCHEMBL12224715 | 0.76 | HRH4 (0.54) | HRH4HRH3TRPV4NSD2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885HTT 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.